prucalopride was approved for use in europe in 2009 in canada in 2011 and in israel in 2014 but has only been recently approved by the food and drug administration for use in the united states the drug has also been tested for the treatment of chronic intestinal pseudo obstruction the primary measure of efficacy in the clinical trials is three or more spontaneous complete bowel movements per week a secondary measure is an increase of at least one complete spontaneous bowel movement per week further measures are improvements in pac qol a quality of life measure and pac sym a range of stool abdominal and rectal symptoms associated with chronic constipation infrequent bowel movements bloating straining abdominal pain and defecation urge with inability to evacuate can be severe symptoms significantly affecting quality of life in three large clinical trials 12 weeks of treatment with prucalopride 2 and 4 mg day resulted in a significantly higher proportion of patients reaching the primary efficacy endpoint of an average of 3 spontaneous complete bowel movements than with placebo there was also significantly improved bowel habit and associated symptoms patient satisfaction with bowel habit and treatment and hr qol in patients with severe